Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 12/20 | 0.44 |
| ▸ | JAK3 | P52333 | 11/20 | 0.44 |
| ▸ | JAK1 | P23458 | 9/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 4/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12876743 | 0.87 | JAK2 (0.53) | JAK2JAK3JAK1TYK2NUDT1 | |
| SCHEMBL1082037 | 0.83 | AXL (0.47) | JAK2JAK3JAK1NOTUMTYK2 | |
| SCHEMBL28798529 | 0.83 | TTBK1 (0.48) | JAK2JAK3JAK1NUDT1MAP2K1 | |
| SCHEMBL29656385 | 0.83 | TTBK1 (0.48) | JAK2JAK3JAK1NUDT1MAP2K1 | |
| SCHEMBL24628649 | 0.81 | JAK2 (0.42) | JAK2JAK3JAK1NOTUMTYK2 | |
| SCHEMBL31175280 | 0.80 | MGLL (0.42) | JAK2JAK3JAK1NOTUMTYK2 | |
| SCHEMBL29588316 | 0.80 | AXL (0.56) | JAK2JAK3JAK1NOTUMTYK2 | |
| SCHEMBL21816126 | 0.80 | MGLL (0.42) | JAK2JAK3JAK1NOTUMTYK2 | |
| SCHEMBL1154022 | 0.80 | AXL (0.56) | JAK2JAK3JAK1NOTUMTYK2 | |
| SCHEMBL22620159 | 0.78 | JAK3 (0.46) | JAK2JAK3JAK1TYK2NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114539245-A | Pyrimidine-fused ring derivative-containing regulator, and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2020223728-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| CN-102711470-A | Novel tricyclic compounds | ABBOTT LAB | 2012-10-03 | — | — | CN | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | CCNI, IL2, IL4I1 | HAVCR2 1006/4885JAK2 206/4885JAK3 845/4885 |
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | HAVCR2 1006/4885JAK2 206/4885JAK3 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.